IT Services - Germany



14.9%

Buy (old: Buy) 12.11.2024

EUR 1.10 (old: EUR 1.10)

Q3 in line with est.; consulting on the road to recovery

Topic: QBY released Q3 results that were largely in line with our estimates on the top- and bottom-line. Especially profitability remains on a strongly improved level compared to the previous year. In detail:

Q3 sales increased 3.5% yoy to € 47.0m (eNuW: € 47.3m; eCons: € 47.4m), again driven by the managed service segment but also a sequential improvement of the consulting segment. Managed service sales increased 6.2% yoy to € 32.9m (eNuW: € 32.8m) and achieved an improved segment gross margin of 79.9% (+1pp yoy). On the other hand, the consulting segment saw a further decline, as sales were down 2.6% yoy to € 14.1m (eNuW: € 14.5m). Yet, we saw a sequential improvement of 4.2% qoq, which is pointing towards a recovery, in our view, as the segment gross margin also improved slightly by 0.4pp qoq to 7.1%. Mind you, management targets to substantially increase the consulting margin going forward, driven by an increased utilization as well as a higher near- and off-shoring ratio (target: 20%; 13% at Q3 '24). Overall gross profit came in at € 7.6m (eNuW: € 7.8m; eCons: € 8.4m, implying a margin of 16.2% (+0.9pp yoy).

Against this backdrop, Q3 EBITDA improved significantly to € 2.2m (vs. € -0.1m in Q3 '23; eNuW: € 2.2m; eCons: € 2.3m), implying a 4.6% margin. The drivers behind the improvement were significant reductions in sales & marketing (-14% yoy) as well as G&A expenses (-12% yoy) following the successful implementation of the *One q.beyond* strategy.


On this basis, management confirmed the FY guidance of \in 192-198m (eNuW: \in 193m; eCons: \in 193m), EBITDA of \in 8-10m (eNuW: \in 9.3m; eCons: \in 9.2m) as well as positive FCF (eNuW: \in 5.6m; eCons: \in 4.4m). In our view, the guidance looks absolutely achievable, especially given the seasonally strong Q4 ahead. At 9M, FCF arrived at \in 4.7m, which compares to \in 2.6m in the same period last year.


Overall, the release fully underpins the case in accordance with management's *Strategy 2025*, targeting an EBTIDA margin of 7-8% (eNuW: 7.1%; eCons: 6.8%) as well as sustained positive net income (eNuW: € 2.1m; eCons: € 1.4m).

Reiterate BUY with an unchanged € 1.10 PT based on DCF.

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	155.2	173.0	189.3	193.2	204.7	216.2
Sales growth	8.2%	11.5%	9.4%	2.1%	5.9%	5.6%
EBITDA	31.7	5.4	5.7	9.3	14.6	17.9
Net debt (if net cash=0)	-54.3	-30.7	-30.4	-36.0	-45.8	-57.7
FCF	-14.9	-4.7	3.9	5.6	9.8	11.9
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	0.08	-0.27	-0.14	-0.04	0.01	0.03
EBITDA margin	20.5%	3.1%	3.0%	4.8%	7.1%	8.3%
ROCE	9.1%	-23.2%	-7.8%	-3.2%	1.8%	5.1%
EV/sales	0.3	0.4	0.4	0.3	0.2	0.2
EV/EBITDA	1.4	12.4	11.6	6.6	3.5	2.2
PER	9.7	-2.8	-5.4	-19.9	88.3	22.9
Adjusted FCF yield	56.2%	-2.1%	-8.6%	7.2%	18.5%	29.5%

Source: Company data, NuWays, Close price as of 04.11.2024





ROCE (2021-26e) 10.0% 0.0% -10.0% -20.0% -30.0% 2021 2022 2023 2024e 2025e 20 Source: NuWays Research

Company description

q.beyond AG is a German-based digital solutions company, active in the fields of cloud management, system applications and products, IoT, and other IT services. The company operates in several countries with a strong focus on the DACH-region.

Share Performance 0.88 0.84 0.80 0.76 0.72 0.64 0.60 0.56 03/24 High/low 52 weeks (€) 0.89 / 0.57-6.1% 3m rel. performance 11.5% 6m rel. performance

12m rel. performance

Market data	
Share price (in €)	0.74
Market cap (in € m)	94.7
Number of shares (in m pcs)	124.6
Enterprise value (in € m)	60.8
Ø trading volume (6 months)	81,317

ldentifier						
Bloomberg	QBY GR					
Reuters	QSCGF					
WKN	513700					
ISIN	DE0005137004					

Key shareholders	
Gerd Eickers	12.7%
Dr. Bernd Schlobohm	12.7%
Free Float	74.7%

Estimates changes					
	<u>2024e</u>	<u>2025e</u>	<u>2026e</u>		
Sales	0%	0%	0%		
EBIT	0%	0%	0%		
FPS	0%	0%	0%		

Comment on changes

Guidance

- Sales: € 192-198m
- EBITDA: € 8-10m
- FCF: positive

Preview / Review - 12.11.2024



Financials

Profit and loss (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	155.2	173.0	189.3	193.2	204.7	216.2
Sales growth	8.2%	11.5%	9.4%	2.1%	5.9%	5.6%
Cost of sales	124.9	145.6	161.7	159.4	163.4	171.2
Gross profit	30.3	27.5	27.6	33.9	41.3	45.0
Sales and marketing	12.6	12.6	14.6	11.4	12.8	13.0
General and administration	17.2	14.9	16.4	13.7	15.4	15.7
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	0.0	0.0	0.0	0.0	0.0	0.0
Other operating expenses	0.0	0.0	0.0	0.0	0.0	0.0
Total operating expenses	0.0	0.0	0.0	0.0	0.0	0.0
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	31.7	5.4	5.7	9.3	14.6	17.9
Depreciation	13.0	12.5	11.0	8.3	8.0	7.7
Amortisation of goodwill	0.0	15.8	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.6	9.4	5.7	4.9	4.5	4.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	15.2	-32.3	-10.9	-3.9	2.1	6.2
Interest income	0.0	0.1	0.7	0.8	0.9	1.1
Interest expenses	0.3	0.2	0.5	0.4	0.4	0.4
Investment income	-0.3	-0.9	-0.5	-0.2	0.0	0.0
Financial result	-0.5	-1.0	-0.3	0.2	0.5	0.7
Recurring pretax income from continuing operations	14.6	-33.2	-11.3	-3.7	2.6	6.9
Extraordinary income/loss	0.0 14.6	0.0 -33.2	0.0	0.0 -3.7	0.0 2.6	0.0
Earnings before taxes	4.8	- 33.2 -0.2	-11.3 5.2	- 3.7 0.0	0.5	6.9
Income tax expense	4.0 9.8	-∪.∠ -33.1	5.∠ -16.4	-3.7	0.5 2.1	1.7 5.2
Net income from continuing operations Income from discontinued operations (net of tax)	0.0	0.0	0.0	-3.7 0.0	0.0	0.0
Net income	9.8	-33.1	-16.4	-3.7	2.1	5.2
Minority interest	0.1	0.2	1.0	1.0	1.0	1.0
Net profit (reported)	9.7	-33.3	-17.5	-4.8	1.1	4.1
Average number of shares	124.5	124.6	124.6	124.6	124.6	124.6
EPS reported	0.08	-0.27	-0.14	-0.04	0.01	0.03
•						
Profit and loss (common size)	2021	2022	2023	2024e	2025e	2026e
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Cost of sales	100.0% 80.5%	100.0% 84.1%	100.0% 85.4%	100.0% 82.5%	100.0% 79.8%	100.0% 79.2%
Sales Cost of sales Gross profit	100.0% 80.5% 19.5%	100.0% 84.1% 15.9%	100.0% 85.4% 14.6%	100.0% 82.5% 17.5%	100.0% 79.8% 20.2%	100.0% 79.2% 20.8%
Sales Cost of sales Gross profit Sales and marketing	100.0% 80.5% 19.5% 8.1%	100.0% 84.1% 15.9% 7.3%	100.0% 85.4% 14.6% 7.7%	100.0% 82.5% 17.5% 5.9%	100.0% 79.8% 20.2% 6.2%	100.0% 79.2% 20.8% 6.0%
Sales Cost of sales Gross profit Sales and marketing General and administration	100.0% 80.5% 19.5% 8.1% 11.1%	100.0% 84.1% 15.9% 7.3% 8.6%	100.0% 85.4% 14.6% 7.7% 8.6%	100.0% 82.5% 17.5% 5.9% 7.1%	100.0% 79.8% 20.2% 6.2% 7.5%	100.0% 79.2% 20.8% 6.0% 7.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	100.0% 80.5% 19.5% 8.1% 11.1% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 0.0% 20.5%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 0.0% 7.1%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 0.0% 8.3%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 0.0% 20.5% 8.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 5.8%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 8.3% 3.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 0.0% 5.8% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 5.0% 0.0% 7.1% 3.9% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 8.3% 3.5% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 5.4% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 5.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 5.1% 3.9% 0.0% 2.2% 0.0% 1.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 0.0% 2.2% 0.0% 1.0% 0.4%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.5%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 0.0% 2.2% 0.0% 1.0% 0.4% 0.2%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.5% 0.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 0.0% 4.0% 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.5% 0.2% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg.	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg.	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.4% 0.2% 0.0% 0.2%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.5% 0.2% 0.0% 0.3%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.3% -0.3% neg5.9%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.4% 0.2% 0.0% 0.2% 1.3%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.2% 0.0% 0.3% 3.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 5.8% 0.0% -5.8% 0.3% -0.3% neg5.9% 0.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.4% 0.2% 0.0% 0.2% 1.3% 0.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.2% 0.0% 0.3% 3.2% 0.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -5.9%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.2% 0.0% 1.3% 0.0% 1.3%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.2% 0.0% 0.3% 3.2% 0.0% 3.2%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% 5.8% 0.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9% 0.0%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.2% 0.0% 1.3% 0.0% 1.3% 20.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 3.5% 0.0% 1.9% 0.0% 2.9% 0.2% 0.0% 0.3% 3.2% 0.0% 3.2% 25.0%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9% 0.0% -1.9%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.2% 0.0% 1.3% 0.0% 1.3% 20.0% 1.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 8.3% 3.5% 0.0% 1.9% 0.5% 0.2% 0.0% 3.2% 0.0% 3.2% 25.0% 2.4%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9% 0.0% -1.9% -1.9%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.2% 0.0% 1.3% 0.0% 1.3% 20.0% 1.0% 1.0%	100.0% 79.2% 6.0% 7.2% 0.0% 0.0% 0.0% 8.3% 3.5% 0.0% 0.5% 0.2% 0.0% 0.3% 3.2% 0.0% 2.50% 2.4% 2.4%
Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 0.0% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 0.0% 0.0% 3.0% 5.8% 0.0% 3.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.5% 17.5% 5.9% 7.1% 0.0% 0.0% 0.0% 4.8% 4.3% 0.0% 2.6% 0.0% -2.0% 0.4% 0.2% -0.1% 0.1% -1.9% 0.0% -1.9%	100.0% 79.8% 20.2% 6.2% 7.5% 0.0% 0.0% 0.0% 7.1% 3.9% 0.0% 2.2% 0.0% 1.0% 0.2% 0.0% 1.3% 0.0% 1.3% 20.0% 1.0%	100.0% 79.2% 20.8% 6.0% 7.2% 0.0% 0.0% 0.0% 8.3% 3.5% 0.0% 1.9% 0.5% 0.2% 0.0% 3.2% 0.0% 3.2% 25.0% 2.4%

Source: Company data, NuWays

Preview / Review - 12.11.2024



Balance sheet (EUR m)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	51.9	28.7	28.1	24.1	20.6	17.6
Property, plant and equipment	39.0	37.8	31.8	26.6	21.9	17.7
Financial assets	6.3	5.3	2.8	2.8	2.8	2.8
FIXED ASSETS	97.2	71.8	62.6	53.5	45.3	38.1
Inventories	0.2	0.2	0.1	0.2	0.3	0.3
Accounts receivable	35.4	39.7	34.1	37.1	39.3	41.5
Other assets and short-term financial assets	5.0	4.9	11.8	11.8	11.8	11.8
Liquid assets	56.7	36.4	37.6	43.2	53.0	64.9
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses CURRENT ASSETS	5.8 103.1	8.2	8.0 91.7	8.0	8.0 112.4	8.0 126.5
TOTAL ASSETS	200.3	89.3 161.1	154.3	100.3 153.8	112.4	126.5
TOTAL AGGETG	200.3	101.1	104.3	133.0	137.7	104.0
SHAREHOLDERS EQUITY	147.1	115.1	97.8	94.9	97.0	102.7
MINORITY INTEREST	0.3	0.5	1.5	1.5	1.5	1.0
Long-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Bonds (long-term)	0.0	0.0	0.0	0.0	0.0	0.0
other interest-bearing liabilities	2.4	5.7	7.2	7.2	7.2	7.2
Provisions for pensions and similar obligations	4.8	2.3	2.1	2.1	2.1	2.1
Other provisions and accrued liabilities	4.7	2.4	5.0	5.0	5.0	5.0
NON-CURRENT LIABILITIES	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	25.4	24.6	25.9	29.1	30.9	32.6
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Accrued taxes	0.0	2.2	6.0	6.0	6.0	6.0
Other liabilities (incl. from lease and rental contracts)	13.7	7.7	6.6	6.6	6.6	6.6
Deferred taxes Deferred income	1.6 0.4	0.0 0.5	0.8 1.3	0.8 0.6	0.8 0.6	0.8 0.6
CURRENT LIABILITIES	39.0	32.4	32.5	35.7	37.4	39.2
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	200.3	161.1	154.3	153.8	157.7	164.6
Balance sheet (common size) Intangible assets	2021 25.9%	2022 17.8%	2023 18.2%	2024e 15.7%	2025e 13.1%	2026e 10.7%
Property, plant and equipment	25.9% 19.5%	23.5%	20.6%	17.3%	13.1%	10.7 %
Financial assets	3.1%	3.3%	1.8%	1.8%	1.8%	1.7%
FIXED ASSETS	48.5%	44.6%	40.6%	34.8%	28.7%	23.1%
Inventories	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%
Accounts receivable	17.7%	24.6%	22.1%	24.1%	24.9%	25.2%
Other assets and short-term financial assets	2.5%	3.0%	7.7%	7.7%	7.5%	7.2%
Liquid assets	28.3%	22.6%	24.4%	28.1%	33.6%	39.5%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses	2.9%	5.1%	5.2%	5.2%	5.1%	4.9%
CURRENT ASSETS	51.5%	55.4%	59.4%	65.2%	71.3%	76.9%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	73.4%	71.5%	63.4%	61.7%	61.5%	62.4%
MINORITY INTEREST	0.1%	0.3%	1.0%	1.0%	1.0%	0.6%
Long-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Bonds (long-term)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
other interest-bearing liabilities	1.2%	3.5%	4.7%	4.7%	4.6%	4.4%
Provisions for pensions and similar obligations	2.4%	1.4%	1.4%	1.4%	1.3%	1.3%
Other provisions and accrued liabilities	2.3%	1.5%	3.2%	3.2%	3.2%	3.0%
NON-CURRENT LIABILITIES	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	12.7%	15.3%	16.8%	18.9%	19.6%	19.8%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accrued taxes	0.0%	1.3%	3.9%	3.9%	3.8%	3.6%
Other liabilities (incl. from lease and rental contracts)	6.8%	4.8%	4.3%	4.3%	4.2%	4.0%
other habilities (moi: nom loads and fortal contracts)	0.070					
Deferred taxes	0.8%	0.0%	0.5%	0.5%	0.5%	0.5%
,		0.0% 0.3%	0.5% 0.9%	0.5% 0.4%	0.5% 0.4%	0.3%
Deferred taxes	0.8%					0.5% 0.3% 23.8% 100.0%

Source: Company data, NuWays

Preview / Review - 12.11.2024



	0004	0000	0000	0004	0005	0000
Cash flow statement (EUR m) Net profit/loss	9.8	-33.1	2023 -16.4	2024e -3.7	2025e 2.1	2026e 5.2
Depreciation of fixed assets (incl. leases)	12.7	-33.1 17.9	11.0	-3. <i>1</i> 8.3	8.0	5.2 7.7
Amortisation of goodwill & intangible assets	3.6	20.0	5.7	4.9	4.5	4.0
Other costs affecting income / expenses	-33.2	-4.3	2.7	0.0	0.0	0.0
Cash flow from operating activities	-12.6	-7.8	1.5	5.7	10.4	12.9
Increase/decrease in inventory	0.0	0.0	0.1	-0.1	-0.0	-0.0
Increase/decrease in accounts receivable	2.4	-4.1	5.5	-2.9	-2.2	-2.2
Increase/decrease in accounts payable	0.5	6.2	1.3	3.2	1.7	1.7
Increase/decrease in other working capital positions	-3.5	-3.9	-3.4	0.0	0.0	0.0
Increase/decrease in working capital	-0.6	-1.7	3.6	0.2	-0.5	-0.5
Cash flow from operating activities	-7.7	-1.3	6.5	9.6	14.1	16.4
CAPEX Powments for acquisitions	7.3 15.5	3.5 10.6	2.6 0.0	4.1 0.0	4.3 0.0	4.5 0.0
Payments for acquisitions Financial investments	6.4	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	53.8	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	24.7	-14.0	-1.7	-4.1	-4.3	-4.5
Cash flow before financing	17.0	-15.2	4.8	5.6	9.8	11.9
Increase/decrease in debt position	-5.4	-0.0	-0.5	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.2	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	-5.1	-3.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities Increase/decrease in liquid assets	-5.3 11.8	-5.1 -20.3	-3.5 1.3	0.0 5.6	0.0 9.8	0.0 11.9
Liquid assets at end of period	56.7	-20.3 36.4	37.6	43.2	53.0	64.9
Elquid assets at end of period	30.7	JU. 4	37.0	70.2	33.0	04.5
Key ratios (EUR m)	2021	2022	2023	2024e	2025e	2026e
P&L growth analysis						
Sales growth	8.2%	11.5%	9.4%	2.1%	5.9%	5.6%
EBITDA growth	-1704.4%	-83.1%	7.1%	61.3%	57.6%	22.5%
EBIT growth EPS growth	-180.6% -148.7%	-312.6% -442.8%	-66.1% -47.5%	-63.9% -72.8%	-154.2% -122.5%	190.0% 285.4%
Efficiency	-140.7 /0	-442.070	-47.570	-12.070	-122.570	203.4 /0
Sales per employee	152.5	153.8	170.3	173.8	181.4	186.0
EBITDA per employee	31.2	4.8	5.2	8.3	12.9	15.4
No. employees (average)	1,018	1,125	1,112	1,112	1,129	1,163
Balance sheet analysis						
Avg. working capital / sales	4.2%	8.7%	4.9%	6.1%	4.2%	4.0%
Inventory turnover (sales/inventory)	623.1	797.3	1,736.5	800.0	800.0	800.0
Accounts receivable turnover	83.3	83.7	65.8	70.0	70.0	70.0
Accounts payable turnover	74.2	61.8	58.5	55.0	55.0	55.0
Cash flow analysis Free cash flow	-14.9	-4.7	3.9	5.6	9.8	11.9
Free cash flow/sales	-9.6%	-2.7%	2.1%	2.9%	4.8%	5.5%
FCF / net profit	neg.	14.3%	neg.	neg.	464.8%	230.4%
Capex / sales	8.8%	2.0%	1.4%	2.1%	2.1%	2.1%
Solvency						
Net debt	-54.3	-30.7	-30.4	-36.0	-45.8	-57.7
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	13.0%	6.8%	10.6%	5.6%	5.0%	5.0%
Returns	0.40/	00.00/	7.00/	0.00/	4.00/	5 40/
ROCE	9.1%	-23.2%	-7.8%	-3.2%	1.8%	5.1%
ROE Adjusted FCF yield	6.6% 56.2%	-28.9% -2.1%	-17.9% -8.6%	-5.0% 7.2%	1.1% 18.5%	4.0% 29.5%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	0.08	-0.27	-0.14	-0.04	0.01	0.03
Average number of shares	124.5	124.6	124.6	124.6	124.6	124.6
Valuation ratios						
P/BV	0.6	8.0	1.0	1.0	1.0	0.9
EV/sales	0.3	0.4	0.4	0.3	0.2	0.2
EV/EBITDA	1.4	12.4	11.6	6.6	3.5	2.2
EV/EBIT	3.0	-2.1	-6.1	-15.4	23.9	6.3
Source: Company data, NuWays						

Preview / Review - 12.11.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
q.beyond AG	2

Historical target p	price and rating changes for	q.beyond AG			
Company	Date	Analyst	Rating	Target Price	Close
q.beyond AG	14.05.2024	Sennewald, Philipp	Buy	EUR 1.10	EUR 0.73

Preview / Review - 12.11.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 12/11/2024 07:25 AM

Date of publication dissemination: 12/11/2024 07:25 AM



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



<u>LinkedIn</u>

